ArticleCancer science2025
Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU+ Endothelial Cells as Key Players in Tumor Progression.
Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Understanding and Overcoming Osteosarcoma Heterogeneity.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Osteosarcoma is a common malignant bone tumor in children and adolescents, characterized by high heterogeneity and poor prognosis. The role of intratumoral heterogeneity (ITH) in osteosarcoma progression remains poorly understood. To explore this, we collected paired tumor tissue samples from the central region (CR) and peripheral region (PR) of six osteosarcoma patients and performed single-cell RNA sequencing. Our findings reveal significant microenvironmental differences between these regions. The CR harbors a higher proportion of tumor cells, while the PR contains a higher proportion of endothelial cells, particularly the CLU+ subcluster. Functionally, the CR hosts a higher proportion of immune-activated myeloid cells and tumor-infiltrating lymphocytes (TILs), whereas the tumor cells in the PR show increased activation of hypoxia-related pathways. In the PR, CLU+ endothelial cells (CLU+_ECs) promote tumor metastasis by interacting with tumor cells through various ligands, including collagen family members, via ITGB1. Furthermore, CLU+_ECs induce CD8+ T cell exhaustion via the Nectin2-TIGIT pathway, suppressing the anti-tumor immune response. Overall, our study highlights the substantial spatial heterogeneity in osteosarcoma and identifies CLU+_ECs in the peripheral region as promising therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.